Diffuse large B-cell lymphoma (DLBCL) is the most common WHO subclassification of B-cell non-Hodgkin lymphoma (NHL), constituting 30--40% of all new cases \[[@B1]\]. Advances in chemoimmunotherapy have included the combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) \[[@B2]\], the regimen most frequently used in fit patients with advanced disease. Although this regimen has resulted in substantial improvements in cure rate, approximately 40% of patients with DLBCL will relapse, most of whom will ultimately succumb to the disease \[[@B3]\]. The need for improved therapeutic options therefore remains.

DLBCL subtypes {#S0001}
==============

The heterogeneity and highly variable clinical course of DLBCL is suggestive of several different phenotypes with divergent responses to therapy. Efforts to define subtypes based on morphology have proven problematic \[[@B4],[@B5]\]. Some prognostic factors, such as the nuclear protein Ki-67, a marker of tumor cell proliferation, predicted survival with the standard regimens of CHOP \[[@B6]\] and, later, R-CHOP \[[@B7]\], but the molecular basis for this remained unknown. Clinical parameter-based models such as the International Prognostic Index (IPI) \[[@B8]\], the revised IPI (R-IPI) \[[@B9]\] and the National Comprehensive Cancer Network IPI (NCCN-IPI) \[[@B10]\] separate patients into distinct prognostic subgroups and have been available for some years; however, the cellular and molecular differences underlying these empirical categories were unclear, and risk scores were of limited utility in stratifying patients for therapeutic trials \[[@B11]\]. The possibility that clinical prognostic categories may be proxies for DLBCL subtypes possessing distinct genetic profiles led to an exploration of gene expression in lymph node biopsy samples from patients with *de novo* DLBCL.

Gene-expression profiling (GEP) using microarrays originally identified two major distinct DLBCL subtypes with expression patterns consistent with different stages of B-cell differentiation: germinal center B-cell-like (GCB) and activated B-cell-like (ABC) \[[@B12]\]. These subtypes differed in the expression of hundreds of genes. DLBCL patients with ABC subtype were found to have significantly (p \< 0.01) shorter survival, with a 5-year overall survival (OS) rate of only 16 versus 76% for those with GCB subtype in the CHOP era \[[@B12]\]. Classification by these cell-of-origin (COO) subtypes proved distinct from IPI risk groups, in fact adding to the prognostic value of IPI, with the ABC subtype predicting significantly (p \< 0.05) worse OS than the GCB subtype among all low-risk IPI patients. Subsequent studies have borne out the poorer survival associated with the ABC subtype, with 5-year OS rates of 60 and 35% in GCB and ABC subtype first-line DLBCL, respectively \[[@B13]\]. Further biological studies revealed different somatic mutation profiles and different signaling pathways, further supporting the notion that ABC and GCB DLBCL are indeed distinct biological subtypes of DLBCL \[[@B14]\].

Additional GEP studies identified a third DLBCL subtype that was neither ABC nor GCB \[[@B13]\]. This heterogeneous subtype was originally referred to as 'type 3' but later would simply be called 'unclassifiable'.

Although genome-wide GEP represented the 'gold standard' of DLBCL subtyping methods, as originally performed it was complex, expensive, time consuming and required fresh or frozen tissue, all of which made it impractical for routine clinical use. Immunohistochemistry (IHC) using formalin-fixed, paraffin-embedded (FFPE) tissue and as few as three immunostains proved more feasible \[[@B15]\] and provided an alternative to GEP. However, IHC at best defines only GCB and non-GCB subtypes and variably assigns the unclassifiable subtype to either category. In addition, while IHC performs relatively well in experienced hands, it is subject to technical and interpretative problems, with highly variable results for interlaboratory comparisons \[[@B16]\]. One study comparing IHC versus GEP subtyping found an IHC misclassification rate of between 30 and 60% for the GCB subset, with a resulting loss of survival prognostic ability \[[@B17]\]. However, despite the considerable loss of precision compared with GEP, the relative convenience and availability of IHC led to its widespread adoption for DLBCL subtyping in the clinic.

Recently, a novel GEP assay for DLBCL subtyping that uses FFPE tissue samples, Lymph2Cx, was developed \[[@B18]\]. Using the commercial NanoString^®^ nCounter^®^ Analysis System (NanoString Technologies, WA, USA) and starting with a set of 93 genes identified as differentiating between ABC and GCB subtypes \[[@B19]\], investigators determined that a set of 15 core genes, along with five housekeeping genes, predicted COO as determined by the 'gold standard' of full GEP. The resulting 20-gene assay was validated in an independent cohort of FFPE tissue samples. The subtype misassignment rate was only 2%, which compares favorably to the corresponding 6--17% rates reported for IHC-based methods ([Figure 1](#F0001){ref-type="fig"}) \[[@B18]\]. Importantly, concordance of COO identification between two independent laboratories was \>95%. The Lymph2Cx assay was further studied in a large population-based cohort of patients treated with R-CHOP and was shown to retain its prognostic value independent of IPI score \[[@B20]\]. Use of this assay in clinical trials such as the ROBUST study described herein is expected to increase the accuracy of subtype classification, an important step in better matching patient to treatment, the goal of precision medicine \[[@B21]\].

![**NanoString gene-expression profiling using the Lymph2Cx assay.**\
DLBCL: Diffuse large B-cell lymphoma; GCB: Germinal center B cell; IHC: Immunohistochemistry.\
Republished with permission from \[[@B18]\] © Clearance Center, Inc.](fon-12-1553-g1){#F0001}

Lenalidomide in DLBCL {#S0002}
=====================

Lenalidomide is an oral immunomodulatory drug that has direct antineoplastic activity, as well as indirect effects mediated via immune cells present in the tumor microenvironment \[[@B22]\]. Lenalidomide targets the E3 ubiquitin ligase cereblon \[[@B23]\]. In preclinical studies lenalidomide exhibits synergy with rituximab \[[@B24],[@B25]\], and clinical experience has associated single-agent and combination lenalidomide with durable responses in multiple types of both indolent and aggressive relapsed/refractory NHL. Lenalidomide is approved by the US FDA for multiple myeloma in combination with dexamethasone and for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality. In mantle cell lymphoma, lenalidomide is FDA approved for relapsed or progressed disease after two prior therapies, one of which included bortezomib \[[@B26]\].

In a xenograft model of DLBCL, lenalidomide had a more pronounced effect on ABC subtype disease than on the non-ABC subtype \[[@B27]\], which was associated with downregulation of the transcription factor IRF4, a downstream target of cereblon, with a consequent downregulation of B-cell receptor-dependent NF-κB. Two clinical studies explored the safety and activity of lenalidomide in relapsed/refractory aggressive NHL, including DLBCL \[[@B28],[@B29]\]. Patients were treated with oral lenalidomide (25 mg daily) on days 1--21 of each 28-day cycle. COO subtyping was not performed. Pooled analysis of the 134 patients with DLBCL from these trials (median age 66 years, median of three prior regimens) revealed an overall response rate (ORR) of 26%, including 9% achieving complete response (CR)/CR unconfirmed. The median duration of response was 6 months. The safety profile of lenalidomide was consistent with that observed in other studies, the most frequent grade 3 or 4 events being reversible neutropenia (22 and 13%), thrombocytopenia (16 and 5%) and anemia (6 and 0.7%) \[[@B30]\].

In a retrospective review of 40 patients with relapsed/refractory DLBCL who were treated with lenalidomide and who had subtype assigned by IHC, a significantly improved response (53 vs 9%, p = 0.006), as well as significantly better median progression-free survival (PFS; 6.2 vs 1.7 months, p = 0.004), was reported in the non-GCB versus GCB subtype \[[@B31]\]. Thus, clinical evidence supported further investigation of lenalidomide in relapsed/refractory DLBCL.

The prospective DLC-001 trial randomized 102 patients with relapsed/refractory DLBCL stratified by COO subtype as determined by IHC using the Hans algorithm \[[@B15]\] to receive either oral lenalidomide (25 mg daily, days 1--21 of each 28-day cycle) or investigator\'s choice monotherapy consisting of single-agent gemcitabine, rituximab, etoposide or oxaliplatin \[[@B32]\]. In this third plus-line population, lenalidomide was associated with improved PFS relative to investigator\'s choice in the overall patient population (13.6 vs 7.9 weeks, p = 0.041). Among lenalidomide-treated patients with DLBCL classified as GCB or non-GCB, ORR was similar (26 vs 29%), but PFS (10.1 vs 15.1 weeks) and OS (30.0 vs 32.3 weeks) were greater in the non-GCB group. Exploratory analysis using microarray GEP found significant efficacy differences between the more precisely defined ABC and GCB groups. Lenalidomide-treated patients with the ABC subtype had improvement in ORR (45 vs 21%), median PFS (82.0 vs 13.2 weeks) and median OS (108.4 vs 30.0 weeks) relative to GCB subtype patients. Thus, GEP-defined subtypes provided superior predictive power relative to IHC.

Data on lenalidomide in first-line DLBCL were provided by two Phase II single-arm studies of lenalidomide plus R-CHOP (R^2^-CHOP). A Mayo Clinic study compared 64 patients with newly diagnosed DLBCL who were treated with oral lenalidomide (25 mg daily, days 1--10) combined with standard R-CHOP21 with a contemporaneously treated, case-matched group of 87 patients treated outside the study with conventional R-CHOP \[[@B33]\]. IHC subtyping was used to determine COO \[[@B15]\]. Among the 60 lenalidomide-treated patients evaluable for response, ORR was 98%, with a CR rate of 80% and a 24-month OS rate of 78%. Not surprisingly, the R-CHOP-treated patients with non-GCB disease experienced poorer 24-month PFS (28 vs 64%) and 24-month OS rates (46 vs 74%) than those with the GCB subtype. In contrast, among patients treated with R^2^-CHOP, both 24-month PFS (60 vs 59%) and OS rates (83 vs 75%) were similar for both COO subtypes ([Table 1](#T1){ref-type="table"}), indicating improved survival for patients with non-GCB disease treated with R^2^-CHOP compared with those treated with R-CHOP.

###### **Outcomes of historical control patients treated with R-CHOP and study patients treated with R^2^-CHOP based on GCB and non-GCB DLBCL subtypes.**

  **Subtype, treatment**   **PFS, % (95% CI)**   **OS, % (95% CI)**                  
  ------------------------ --------------------- -------------------- -------------- --------------
  GCB:                                                                                
  -- R-CHOP                73 (62--85)           64 (53--78)          90 (82--98)    74 (63--86)
  -- R^2^-CHOP             64 (49--84)           59 (44--80)          88 (77--100)   75 (61--93)
  Non-GCB:                                                                            
  -- R-CHOP                39 (25--62)           28 (15--51)          61 (45--82)    46 (30--69)
  -- R^2^-CHOP             72 (55--94)           60 (41--87)          95 (87--100)   83 (67--100)

GCB: Germinal center B cell; OS: Overall survival; PFS: Progression-free survival; R-CHOP: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP: lenalidomide plus R-CHOP.

Data taken from \[[@B33]\].

In the multicenter FIL REAL07 study, 49 patients aged 64--71 years with newly diagnosed DLBCL or grade 3b follicular lymphoma received 15 mg oral lenalidomide on days 1--14 of six standard cycles of R-CHOP21 \[[@B34]\]. Subtyping was performed by IHC, and final response was assessed by PET scan. The ORR was 92% (86% CR). Once again, patients with the non-GCB subtype had PFS similar to those with GCB as the cell-of-origin ([Figure 2](#F0002){ref-type="fig"}). The 2-year PFS rates were 81 and 71% in these subgroups, respectively.

![**Progression-free survival by cell-of-origin in the Fondazione Italiana Linfomi REAL07 study.**\
GCB: Germinal center B cell.\
Reprinted with permission from \[[@B34]\] © Elsevier (2014).](fon-12-1553-g2){#F0002}

In both first-line R^2^-CHOP studies, grade 3 or 4 adverse events (AEs) were primarily hematologic and consistent with toxicities expected for R-CHOP alone. The most common grade 3 or 4 adverse events were neutropenia (88 and 79%), leukopenia (80 and 59%) and thrombocytopenia (44 and 30%) in the Mayo Clinic and FIL studies, respectively \[[@B33],[@B34]\]. In both studies, nonhematologic adverse events were infrequent. In the Mayo Clinic study, nonhematologic AEs were seen in 25% of patients, with two patients (3%) experiencing a grade 4 event (one sepsis, one intra-abdominal hemorrhage) and one (2%) experiencing grade 5 sepsis. In the FIL study, the most common nonhematologic AEs were neurological (4%) and deep vein thrombosis (4%). One patient (2%) taking cotrimoxazole discontinued lenalidomide due to grade 3 skin rash.

A recent meta-analysis of lenalidomide studies in first- and second-line DLBCL that included data from these two trials found no significant difference in outcomes between lenalidomide-treated patients with GCB and non-GCB disease, concluding that the addition of lenalidomide to R-CHOP appears to mitigate the unfavorable effects of non-GCB phenotype on outcome \[[@B35]\]. Thus, clinical evidence suggests that the R^2^-CHOP regimen warrants further follow-up in first-line DLBCL. In addition, the exploratory results from the DLC-001 study showing greater improvements in outcomes for patients with the ABC subtype (determined by genome-wide GEP) compared with the less specific non-GCB subtype (determined by IHC) needed to be taken into account in designing subsequent DLBCL studies. The development of a validated 'gene signature' assay capable of rapidly distinguishing between ABC and GCB subtypes on the basis of a limited number of genes and using FFPE tissue could provide a practical alternative for assuring accurate subtype designation. Such an assay should allow for appropriate patient selection and a more straightforward interpretation of trial results. With this in mind, a large, randomized study of R^2^-CHOP versus placebo plus standard R-CHOP chemotherapy in patients with newly diagnosed ABC subtype DLBCL was designed.

ROBUST {#S0003}
======

• Study objectives {#S0004}
------------------

The primary objective of ROBUST (DLC-002; NCT02285062), a randomized, double-blind, placebo-controlled, global, Phase III study, is to evaluate the efficacy of R^2^-CHOP versus placebo-R-CHOP in patients with previously untreated ABC-type DLBCL as determined by GEP. The secondary study objective is to compare the safety of R^2^-CHOP versus placebo-R-CHOP in this patient population.

Exploratory objectives are to compare the time to second progression after randomization (PFS2), to explore genetic mutations in patients receiving R^2^-CHOP versus placebo-R-CHOP, to explore minimal residual disease (MRD) and clonal heterogeneity/succession in patients receiving R^2^-CHOP versus placebo-R-CHOP who achieve CR, to investigate molecular markers related to lenalidomide\'s mechanism of action, and to evaluate the pharmacokinetics (PK) of lenalidomide when coadministered with and without R-CHOP.

• Study end points {#S0005}
------------------

The primary end point is PFS. Secondary end points are event-free survival, OS, CR rate, duration of CR, time to next lymphoma therapy, ORR and health-related quality of life as measured by the EuroQuol 5 Dimension Questionnaire (EQ-5D) \[[@B36]\] and the Functional Assessment of Cancer Therapy for Patients with Lymphoma (FACT-Lym) \[[@B37]\] standardized measures of health status.

Exploratory end points are PFS2, correlation of MRD status with clinical outcomes such as PFS and OS, and sensitivity and specificity of the MRD next-generation sequencing test, correlation of pretreatment levels of molecular markers with clinical outcome, incidence of mutations of selected genes and correlation with clinical outcome and PK parameters of lenalidomide.

• Key eligibility criteria {#S0006}
--------------------------

All patients must provide written informed consent. Other inclusion criteria are shown in [Table 2](#T2){ref-type="table"}.

###### **Key ROBUST inclusion and exclusion criteria.**

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Inclusion criteria**                                                                            **Exclusion criteria**
  ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Previously untreated, histologically confirmed ABC-type^†^ CD20^+^ DLBCL\                         Unclassifiable or GCB-type DLBCL\
  Measurable disease ≥1.5 cm in the longest diameter and in 2 perpendicular directions by CT/MRI\   History of other malignancies, unless disease free for ≥5 years\
  Age, 18--80 years^‡^\                                                                             Evidence of transformed NHL or composite DLBCL/FL\
  International Prognostic Index score ≥2\                                                          Left ventricular ejection fraction \<45%\
  Absolute neutrophil count ≥1.5 × 10^9^/l^§^\                                                      Grade ≥2 peripheral neuropathy
  Platelet count ≥75 × 10^9^/l^¶^\                                                                  
  Hemoglobin ≥7.5 g/dl\                                                                             
  Calculated creatinine clearance ≥30 ml/min\                                                       
  Contraception as appropriate                                                                      

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^As determined by the validated gene-expression profiling assay performed on the NanoString nCounter Analysis System and assessed by central pathology.

^‡^At investigator\'s discretion, patients over 80 years are eligible if their Eastern Cooperative Oncology Group performance status ≤1, each organ system score is ≤2 using the modified cumulative illness rating scale for comorbidity, and if they are otherwise eligible for R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) per local practice.

^§^Unless secondary to bone marrow involvement, where limit is ≥1.0 × 10^9^/l.

^¶^Unless secondary to bone marrow involvement, where limit is ≥50 × 10^9^/l.

ABC: Activated B cell; CT: Computed tomography; DLBCL: Diffuse large B-cell lymphoma; FL: Follicular lymphoma; GCB: Germinal center B cell; NHL: Non-Hodgkin lymphoma.

In ROBUST, DLBCL subtype is determined at screening using an investigational assay based on the previously described Lymph2Cx assay (NanoString Technologies, Inc., Seattle, WA, USA) \[[@B38]\]. A central pathology laboratory in Europe or the USA evaluates FFPE lymph node or tumor samples obtained through surgical incision or excision biopsy or core needle biopsy \[[@B39]\]. Central pathology review of diagnosis, subtype and CD20+ status is completed and the results transmitted within 3 calendar days (inclusive of weekends and holidays) of sample receipt, thus minimizing treatment delays.

• Study design & treatment {#S0007}
--------------------------

Approximately 560 eligible patients will be randomized 1:1 to receive R^2^-CHOP or placebo-R-CHOP ([Figure 3](#F0003){ref-type="fig"}). Randomization is via the interactive voice response system and stratified according to IPI score, presence of bulky disease and age. Patients and investigators are blinded to treatment assignment. The regimens are administered as shown in [Table 3](#T3){ref-type="table"}. At investigator\'s discretion prephase treatment with corticosteroids according to local practice is permitted. Patients receive six cycles of treatment, and if standard of care per the local practice, two additional doses of single-agent rituximab may be administered. Treatment continues until completion, unacceptable toxicity, inadequate response to treatment is determined, disease progression, death or withdrawal of consent, whichever occurs first. Primary neutropenia prophylaxis with G-CSF or GM-CSF is mandatory, with dosing and schedule per local practice.

![**ROBUST study design.**\
^†^Option for two additional rituximab doses after completing treatmentregimen (if considered standard of care per local practice), and optionfor pre-specified local radiotherapy for bulky disease after study chemotherapy.\
ABC: Activated B cell; DLBCL: Diffuse large B-cell lymphoma; GCB: Germinal center B cell; GEP: Gene-expression profiling; R-CHOP: Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.](fon-12-1553-g3){#F0003}

###### **R^2^-CHOP and placebo-R-CHOP dosing and administration.**

  **Drug**                       **Dose**                   **Dosing days (every 21 days)**
  ------------------------------ -------------------------- -----------------------------------------
  Lenalidomide/placebo p.o.      15 mg                      1--14
  Rituximab iv.                  375 mg/m^2^                -1 or 1
  Cyclophosphamide iv.           750 mg/m^2^                1
  Doxorubicin iv.                50 mg/m^2^                 1
  Vincristine iv.                1.4 mg/m^2^ (max 2.0 mg)   1
  Predinsone/prednisolone p.o.   100 mg                     1--5 (or day 1 iv. methylprednisone)^†^

^†^Per local practice.

iv.: Intravenous; p.o.: Oral.

Investigators may prospectively choose to administer local radiotherapy after study chemotherapy for treatment of a particular site of bulky disease (defined as ≥7 cm). Follow-up begins upon early treatment discontinuation or after six cycles of treatment. Patients are followed for first and second progression, subsequent antilymphoma therapies, development of second primary malignancies and OS.

• Evaluations {#S0008}
-------------

Efficacy is evaluated per the International Working Group Response Criteria for NHL \[[@B40]\], and PET scans are interpreted according to the Deauville criteria \[[@B41]\]. CT scans are done at screening, midcycle, end of treatment and at 12-week intervals during years 1--3 of the 5-year follow-up period. PET scans are done at screening and at the end of treatment. MRD is assessed using next-generation sequencing, and sample collection is matched to the CT scan assessment schedule. Throughout the study, investigators perform real-time efficacy assessments. Real-time end-of-treatment assessment and batched review of follow-up scans are performed by central radiology. For the primary analysis, PFS events are determined by central review. Quality of life assessment via patient-completed EQ-5D and FACT-Lym instruments is done at screening, after cycles 3 and 6 and every 12 weeks during follow-up, beginning with week 34.

Safety, including the occurrence of second primary malignancies as events of interest, is monitored throughout the study. Adverse events are coded according to the Medical Dictionary for Regulatory Affairs and are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

• Statistical considerations {#S0009}
----------------------------

The intent-to-treat population is defined as all patients who are randomized into the trial, regardless of whether they received study treatment. The safety population is defined as all patients who have received at least one dose of study drug. The primary end point, PFS, will be analyzed in the intent-to-treat population. The safety population will be used for all safety analyses.

At the predetermined sample size (560 patients) ROBUST has a 90% power to detect a hazard ratio (HR) of 0.625, that is, a 37.5% reduction in the PFS HR, at a two-sided 0.05 significance level. Median PFS in the control arm is assumed to be approximately 24 months. An interim analysis for futility is preplanned. Kaplan--Meier estimates of survival will be calculated for time-to-event end points. A Cox proportional hazard model will be used to estimate HRs with 95% CIs. Treatment effects, however, will be determined by the p-value from the stratified log-rank test.

• Study status {#S0010}
--------------

ROBUST is an international study, with centers located in North America, Europe, Asia and Australia ([Figure 4](#F0004){ref-type="fig"}). A list of study centers can be found on the [ClinicalTrials.gov](http://ClinicalTrials.gov) website \[[@B42]\]. Enrollment was initiated in January 2015, with expected accrual completion in October 2017. This study is sponsored by Celgene and is a joint scientific collaboration among Fondazione Italiana Linfomi, Mayo Clinic, and Celgene. Further information is available at [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02285062).

![**ROBUST participating countries as of February 2016.**\
PAC: Pacific.](fon-12-1553-g4){#F0004}

Conclusion {#S0011}
==========

Recent years bear witness to continued advances in the treatment of hematologic malignancies. In the case of DLBCL, the addition of the anti-CD20 monoclonal antibody rituximab to CHOP was found to significantly improve median PFS and improve median OS in elderly patients with previously untreated disease \[[@B43]\], leading to the widespread adoption of rituximab in standard DLBCL regimens \[[@B44]\]. Using GEP, researchers began to unravel the molecular basis for the divergent outcomes associated with the single disease of DLBCL, identifying a major subtype, ABC, which is associated with poorer survival \[[@B12]\]. Assays for the DLBCL-COO subtypes of GCB and non-GCB using IHC became amenable for routine use, initially of value for predicting prognosis and subsequently for identifying the non-GCB cases associated with inferior survival as candidates for alternative therapies. The demonstration of single-agent activity of lenalidomide in relapsed DLBCL and its mechanism of action that differed from those of other agents in R-CHOP paved the way for the development of the R^2^-CHOP regimen. Indeed, the addition of the immunomodulatory agent lenalidomide to standard first-line R-CHOP ranks among the most promising new regimens to date, providing outcomes for patients with non-GCB disease similar to those of patients with the GCB-COO in two Phase II studies \[[@B33],[@B34]\]. Discrepancies between the classifications provided by IHC subtyping and those obtained using the 'gold standard' GEP method and the need for confirmatory results in a large, randomized trial remain. ROBUST will address both of these important issues. Rapid COO classification by a validated companion diagnostic GEP assay using routinely available FFPE biopsy tissue will improve the speed and accuracy of COO classifications and allow inclusion of only ABC patients, the group hypothesized to derive the greatest benefit from R^2^-CHOP therapy. Increasing the accuracy of routine clinical DLBCL molecular subtyping is an important step in the evolution of better therapies for patients with DLBCL and a prerequisite for the advancement of precision medicine \[[@B21]\].

###### EXECUTIVE SUMMARY

**Diffuse large B-cell lymphoma subtypes** {#S0012}
------------------------------------------

-   The ability to classify diffuse large B-cell lymphoma (DLBCL) by cell-of-origin (COO) led to the identification of the activated B cell (ABC) subtype and its association with poor survival relative to the germinal center B-cell (GCB) subtype.

-   The original 'gold standard' assay for DLBCL using genome-wide gene-expression profiling (GEP) was unsuitable for routine clinical use; instead, immunohistochemistry (IHC), with a higher rate of misclassification, was generally employed to ascertain GCB versus non-GCB subtypes.

-   The Lymph2Cx assay, a novel 20-gene GEP assay that is highly concordant with the 'gold standard' assay for DLBCL and enables analysis of formalin-fixed, paraffin-embedded biopsy samples with a turnaround of 3 calendar days, was developed to overcome limitations of IHC classifiers.

**Lenalidomide in DLBCL** {#S0013}
-------------------------

-   Lenalidomide is an oral immunomodulatory drug that has antineoplastic activity, as well as indirect effects mediated by immune cells present in the tumor microenvironment.

-   The DLC001 trial comparing lenalidomide monotherapy with investigator\'s choice monotherapy in pretreated DLBCL found significantly improved progression-free survival (PFS) in the lenalidomide arm. Exploratory analysis in lenalidomide-treated patients found improvements in response and survival in patients with the ABC subtype relative to the GCB group.

-   In two Phase II, single-arm studies of previously untreated DLBCL, R^2^-CHOP (lenalidomide plus rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone \[R-CHOP\]) provided similar PFS benefits to patients in both non-GCB and GCB subgroups, suggesting more pronounced benefits in the former, which is primarily the ABC subtype.

**ROBUST** {#S0014}
----------

-   ROBUST is a randomized, double-blind, placebo-controlled, global, Phase III study evaluating the efficacy and safety of R^2^-CHOP versus placebo-R-CHOP in patients with previously untreated ABC-type DLBCL.

-   The primary end point is PFS, as assessed by central review. Secondary end points include event-free survival, overall survival, complete response rate, duration of response, time to next lymphoma treatment, overall response rate and health-related quality of life.

-   Key eligibility criteria include previously untreated, histologically confirmed ABC-type CD20+ DLBCL.

-   To ensure accurate diagnosis, COO subtype is determined using a clinical trial assay version of Lymph2Cx, a novel 20-gene GEP assay that analyzes formalin-fixed, paraffin-embedded biopsy samples with a turnaround of 3 calendar days.

-   Other inclusion criteria include measurable disease and International Prognostic Index score ≥2.

-   Approximately 560 patients will be randomized 1:1 to receive six cycles of R^2^-CHOP (15 mg oral lenalidomide daily, days 1--14, plus standard R-CHOP21) or to placebo (15 mg daily, days 1--14) plus R-CHOP21.

-   Two additional doses of single-agent rituximab may be administered if standard of care per local practice.

-   Treatment continues until completion, unacceptable toxicity, inadequate response, disease progression or withdrawal of consent.

-   The study has a 90% power to detect a hazard ratio of 0.625 at a two-sided significance level of 0.05.

-   An interim analysis for futility is planned at 50% of events.

-   ROBUST is enrolling at centers in North America, Europe, Asia and Australia.

-   A list of study centers can be found at \[[@B42]\].

-   Enrollment began in January 2015, with accrual expected to be completed in October 2017.
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